Lantus site tops in consumer satisfaction: study

Share this article:

The product site for Sanofi-Aventis's insulin injection Lantus received the highest mark in terms of consumer satisfaction, according to a Manhattan Research study.

The website (which features optional registration for the “Lantus Connection” community and support program) provides “real stories, real tips and real support” for diabetics, and offers “healthcare professional visit guides” in pdf form for download.

In order to join the Lantus community, consumers must input basic information, such as name, address, type of diabetes, current treatments, results from the most recent A1C test and answer several attitudinal statements. For example, registrants are asked whether their diabetes is “completely under control,” if they “feel frazzled by not being able to control my blood sugar” and if they are “interested in learning about insulin,” and whether “having to go on (having gone on) insulin means that I have failed at controlling my blood sugar.” After providing this information, consumers presumably receive a customized newsletter via email.

Other top brand sites, according to the study, are GlaxoSmithKline's Advair website and Merck's Singulair website, coming in at number two and three, respectively.

The following sites also received high consumer satisfaction levels, according to the study: Bristol-Myers Squibb's Abilify, Pfizer's Caduet, Merck's Januvia, Bayer's Mirena, AstraZeneca's Nexium/purplepill.com, Takeda's Prevacid and Wyeth's Protonix.

“While driving visitors to sites is critical, engaging and retaining them will provide the most strategic value to the brand,” said Mark Bard, president of Manhattan Research, in a statement.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...